上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2022 , Vol. 42 >Issue 4: 545 - 550

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.04.018

综述

生酮饮食调控肠道菌群在疾病治疗中的研究进展

  • 吴亚 ,
  • 殷峻
展开
  • 1.上海市第八人民医院内分泌科，上海 200235
    2.上海交通大学医学院附属第六人民医院内分泌代谢科，上海市糖尿病临床医学中心，上海市内分泌代谢病临床医学中心，上海 200233
吴亚（1992—），女，住院医师，硕士；电子信箱：18360868900@163.com。
殷峻，电子信箱：yinjun@sjtu.edu.cn。

收稿日期: 2021-12-31

  录用日期: 2021-03-25

  网络出版日期: 2022-04-28

基金资助

国家自然科学基金(82070885);上海市教育委员会高峰高原学科建设计划(20172025)

收起

Research progress of ketogenic diet regulating intestinal microbiome in the treatment of diseases

  • Ya WU ,
  • Jun YIN
Expand
  • 1.Department of Endocrinology, Shanghai Eighth People's Hospital, Shanghai 200235, China
    2.Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Clinical Center for Endocrinology and Metabolic Diseases, Shanghai 200233, China
YIN Jun, E-mail: yinjun@sjtu.edu.cn.

Received date: 2021-12-31

  Accepted date: 2021-03-25

  Online published: 2022-04-28

Supported by

National Natural Science Foundation of China(82070885);Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support(20172025)

Fold

摘要

生酮饮食是一种高脂肪、极低碳水化合物、适量蛋白质和其他营养素的饮食模式，最早被用于治疗儿童癫痫。随着医学的不断发展，生酮饮食被逐渐用于其他疾病的辅助治疗，但其具体作用机制尚不明确。最近的研究发现，生酮饮食可影响肠道菌群的多样性和数量，对宿主的健康有着重要的意义。研究表明，生酮饮食可以增加小鼠肠道中的嗜黏蛋白阿克曼菌（Akkermansia muciniphila，A. muciniphila）和副拟杆菌的丰度，导致γ-谷氨酰氨基酸生成减少、海马体中γ-氨基丁酸/谷氨酸比值升高，从而降低癫痫的发作频率；A. muciniphila丰度增加还可以改善脑血管功能，降低阿尔茨海默病的发生风险。另外，生酮饮食还可降低小鼠肠道双歧杆菌的丰度，导致肠道乳酸水平下降，从而改善认知和记忆功能；同时，该丰度的下降还可导致具有促炎作用的辅助性T细胞17水平的下降，从而治疗肥胖。基于此，该文就生酮饮食调控肠道菌群在神经系统疾病（包括癫痫、阿尔茨海默病、多发性硬化症、孤独症）、代谢性疾病（包括糖尿病、肥胖）及肿瘤中的治疗作用及可能的机制进行综述。

关键词： 生酮饮食; 嗜黏蛋白阿克曼菌; 双歧杆菌; 糖尿病; 肥胖

本文引用格式

吴亚 , 殷峻 . 生酮饮食调控肠道菌群在疾病治疗中的研究进展[J]. 上海交通大学学报（医学版）, 2022 , 42(4) : 545 -550 . DOI: 10.3969/j.issn.1674-8115.2022.04.018

Abstract

Ketogenic diet is a high-fat, very low-carbohydrate, appropriate amount of protein and other nutrients diet. It was first used to treat children's epilepsy. With the continuous development of medicine, ketogenic diet has been gradually used in the adjuvant treatment of other diseases, but its specific mechanism is not clear. Recent studies have shown that ketogenic diet can affect the diversity and quantity of intestinal flora, which is of great significance to the health of the host. Studies have also shown that ketogenic diet can increase the abundance of Akkermansia muciniphila (A. muciniphila) and Parabacteroides in mouse intestine, resulting in decreased subset of gamma-glutamylated amino acids and increased ratio of hippocampal gamma-aminobutyric acid and glutamate, which could reduce the frequency of seizures. Elevated abundance of A. muciniphila can also improve cerebrovascular function, and then reduce the risk of Alzheimer's disease. Besides, ketogenic diet can also decrease the abundance of Bifidobacterium in mouse intestine, resulting in the decrease of intestinal lactic acid level and pro-inflammatory T helper 17 cell (Th17 cell) level, which could improve cognitive and memory function and treat obesity, respectively. This article reviews the therapeutic effects and possible mechanisms of ketogenic diet on the regulation of intestinal flora in neurological diseases (epilepsy, Alzheimer's disease, multiple sclerosis and autism), metabolic diseases (diabetes mellitus and obesity), and tumors.

Key words： ketogenic diet; Akkermansia muciniphila （A. muciniphila）; Bifidobacterium; diabetes mellitus; obesity

参考文献

1 REDDEL S, PUTIGNANI L, DEL CHIERICO F. The impact of low-FODMAPs, gluten-free, and ketogenic diets on gut microbiota modulation in pathological conditions[J]. Nutrients, 2019, 11(2): E373.
2 KLEMENT R J, PAZIENZA V. Impact of different types of diet on gut microbiota profiles and cancer prevention and treatment[J]. Medicina (Kaunas), 2019, 55(4): E84.
3 SENDER R, FUCHS S, MILO R. Revised estimates for the number of human and bacteria cells in the body[J]. PLoS Biol, 2016, 14(8): e1002533.
4 JANDHYALA S M, TALUKDAR R, SUBRAMANYAM C, et al. Role of the normal gut microbiota[J]. World J Gastroenterol, 2015, 21(29): 8787-8803.
5 PANEBIANCO C, ANDRIULLI A, PAZIENZA V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies[J]. Microbiome, 2018, 6(1): 92.
6 PETERSEN C, ROUND J L. Defining dysbiosis and its influence on host immunity and disease[J]. Cell Microbiol, 2014, 16(7): 1024-1033.
7 GIBIINO G, LOPETUSO L R, SCALDAFERRI F, et al. Exploring Bacteroidetes: metabolic key points and immunological tricks of our gut commensals[J]. Dig Liver Dis, 2018, 50(7): 635-639.
8 DEGRUTTOLA A K, LOW D, MIZOGUCHI A, et al. Current understanding of dysbiosis in disease in human and animal models[J]. Inflamm Bowel Dis, 2016, 22(5): 1137-1150.
9 NIH HMP WORKING GROUP, PETERSON J, GARGES S, et al. The NIH human microbiome project[J]. Genome Res, 2009, 19(12): 2317-2323.
10 TANEJA V. Arthritis susceptibility and the gut microbiome[J]. FEBS Lett, 2014, 588(22): 4244-4249.
11 DAVID L A, MAURICE C F, CARMODY R N, et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature, 2014, 505(7484): 559-563.
12 PAOLI A, MANCIN L, BIANCO A, et al. Ketogenic diet and microbiota: friends or enemies?[J]. Genes (Basel), 2019, 10(7): 534.
13 NAGPAL R, NETH B J, WANG S H, et al. Gut mycobiome and its interaction with diet, gut bacteria and Alzheimer's disease markers in subjects with mild cognitive impairment: a pilot study[J]. EBioMedicine, 2020, 59: 102950.
14 MILLER V J, VILLAMENA F A, VOLEK J S. Nutritional ketosis and mitohormesis: potential implications for mitochondrial function and human health[J]. J Nutr Metab, 2018, 2018: 5157645.
15 XIE G, ZHOU Q, QIU C Z, et al. Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy[J]. World J Gastroenterol, 2017, 23(33): 6164-6171.
16 ZHANG Y J, ZHOU S Z, ZHOU Y F, et al. Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet[J]. Epilepsy Res, 2018, 145: 163-168.
17 MA D, WANG A C, PARIKH I, et al. Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice[J]. Sci Rep, 2018, 8(1): 6670.
18 ZHANG T, LI Q Q, CHENG L, et al. Akkermansia muciniphila is a promising probiotic[J]. Microb Biotechnol, 2019, 12(6): 1109-1125.
19 OLSON C A, VUONG H E, YANO J M, et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet[J]. Cell, 2018, 174(2): 497.
20 NAGPAL R, NETH B J, WANG S H, et al. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment[J]. EBioMedicine, 2019, 47: 529-542.
21 RAO S S C, REHMAN A, YU S, et al. Brain fogginess, gas and bloating: a link between SIBO, probiotics and metabolic acidosis[J]. Clin Transl Gastroenterol, 2018, 9(6): 162.
22 SWIDSINSKI A, D?RFFEL Y, LOENING-BAUCKE V, et al. Reduced mass and diversity of the colonic microbiome in patients with multiple sclerosis and their improvement with ketogenic diet[J]. Front Microbiol, 2017, 8: 1141.
23 RUSKIN D N, FORTIN J A, BISNAUTH S N, et al. Ketogenic diets improve behaviors associated with autism spectrum disorder in a sex-specific manner in the EL mouse[J]. Physiol Behav, 2017, 168: 138-145.
24 CASTRO K, BARONIO D, PERRY I S, et al. The effect of ketogenic diet in an animal model of autism induced by prenatal exposure to valproic acid[J]. Nutr Neurosci, 2017, 20(6): 343-350.
25 MU C L, CORLEY M J, LEE R W Y, et al. Metabolic framework for the improvement of autism spectrum disorders by a modified ketogenic diet: a pilot study[J]. J Proteome Res, 2020, 19(1): 382-390.
26 AHN Y, NAROUS M, TOBIAS R, et al. The ketogenic diet modifies social and metabolic alterations identified in the prenatal valproic acid model of autism spectrum disorder[J]. Dev Neurosci, 2014, 36(5): 371-380.
27 NEWELL C, BOMHOF M R, REIMER R A, et al. Ketogenic diet modifies the gut microbiota in a murine model of autism spectrum disorder[J]. Mol Autism, 2016, 7(1): 37.
28 TINGUELY D, GROSS J, KOSINSKI C. Efficacy of ketogenic diets on type 2 diabetes: a systematic review[J]. Curr Diab Rep, 2021, 21(9): 32.
29 REN M X, ZHANG H Y, QI J D, et al. An almond-based low carbohydrate diet improves depression and glycometabolism in patients with type 2 diabetes through modulating gut microbiota and GLP-1: a randomized controlled trial[J]. Nutrients, 2020, 12(10): E3036.
30 ANG Q Y, ALEXANDER M, NEWMAN J C, et al. Ketogenic diets alter the gut microbiome resulting in decreased intestinal Th17 cells[J]. Cell, 2020, 181(6): 1263-1275.e16.
31 LI J, ZHANG H Y, DAI Z. Cancer treatment with the ketogenic diet: a systematic review and meta-analysis of animal studies[J]. Front Nutr, 2021, 8: 594408.
32 LANE J, BROWN N I, WILLIAMS S, et al. Ketogenic diet for cancer: critical assessment and research recommendations[J]. Nutrients, 2021, 13(10): 3562.
33 MUNDI M S, MOHAMED ELFADIL O, PATEL I, et al. Ketogenic diet and cancer: fad or fabulous?[J]. JPEN J Parenter Enteral Nutr, 2021, 45(S2): 26-32.
34 FERRERE G, ALOU M T, LIU P, et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade[J]. JCI Insight, 2021, 6(2): e145207.
35 WELLS J, SWAMINATHAN A, PASEKA J, et al. Efficacy and safety of a ketogenic diet in children and adolescents with refractory epilepsy: a review[J]. Nutrients, 2020, 12(6): E1809.
36 BOLLA A M, CARETTO A, LAURENZI A, et al. Low-carb and ketogenic diets in type 1 and type 2 diabetes[J]. Nutrients, 2019, 11(5): E962.
Options
文章导航

/

〈 〉